Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Sep 2012

Description:

Patients:
This phase 3 study involved 800 men with castration-resistant prostate cancer who had undergone chemotherapy. The median patient age was 69 years.

Treatment:
Patients were treated with the biologic therapy agent enzalutamide, an inhibitor of the androgen-receptor-signaling pathway in cells, which is involved in prostate cancer growth.

Toxicities:
There were 23 treatment-related deaths due to unspecified causes. Grade 3 or higher fatigue, cardiac disorder, and seizure were also reported.

Results:
The median overall survival was 18.4 months.

Support:
This study was supported by Medivation and Astellas Pharma Global Development.

Correspondence: Dr. Howard I. Scher; email: [email protected]



Back